Our systems have detected that you are using a computer with an IP address located in the USA.
If you are currently not located in the USA, please click “Continue” in order to access our Website.

Local restrictions - provision of cross-border services

Swissquote Bank Ltd (“Swissquote”) is a bank licensed in Switzerland under the supervision of the Swiss Financial Market Supervisory Authority (FINMA). Swissquote is not authorized as a bank or broker by any US authority (such as the CFTC or SEC) neither is it authorized to disseminate offering and solicitation materials for offshore sales of securities and investment services, to make financial promotion or conduct investment or banking activity in the USA whatsoever.

This website may however contain information about services and products that may be considered by US authorities as an invitation or inducement to engage in investment activity having an effect in the USA.

By clicking “Continue”, you confirm that you have read and understood this legal information and that you access the website on your own initiative and without any solicitation from Swissquote.


The high-tech syringe

With three new subsidiaries (in Belgium, Spain and Poland) opened in October, Ypsomed continues to expand. Its products are now available in approximately 40 countries, including the United States and China. “Ypsomed is successfully carrying out its international growth strategy,” said Jérôme Schupp, independent analyst. “This ensures a regular increase in revenue.”

The medtech company manufactures syringe systems designed for diabetics. “This is a potentially enormous market,” said Schupp. According to the World Health Organization (WHO), 440 million people suffer from diabetes worldwide. This number is expected to increase, reaching 650 million by 2040.

To stand out from the competition, Ypsomed is developing new wireless products that can better monitor blood sugar levels. “This type of innovation is positive, but Ypsomed’s main focus is its trustworthy relationship with its clients,” said Schupp. “When patients who wear a permanent insulin pump like a certain brand, they remain loyal to that brand. Ypsomed has proved that its injection systems work well. That’s the company’s biggest strength.”

The only foreseeable problem is the break from US distributor Insulet, as the distribution agreement between the two will end in mid-2018. The partnership brought in as much as 120 million Swiss francs for Ypsomed in 2016. The end of the agreement will have consequences for 2018 profits. But Schupp isn’t concerned: “Ypsomed is a safe bet. It is a good investment, with a vision in the mid to long term.”


Insulin pumps specialist, the company is growing steadily

  • Foundation: 2003
  • Headquarter: Burgdorf (BE)
  • Revenues: CHF 389.6 Million
  • Effectives: 1'350